Amplia Therapeutics halted recruitment in its Phase 2 Amplicity trial in advanced pancreatic cancer after three dose-limiting toxicities linked to a modified FOLFIRINOX regimen combined with narmafotinib (AMP-945). The company attributed the pause to safety signals observed with the chemotherapy backbone rather than a stand-alone narmafotinib issue. The trial continues in the provided context as Amplia evaluates next steps following the DLT outcome. For pancreatic cancer programs, the combination of FOLFIRINOX and targeted agents is particularly sensitive to tolerability constraints, and dose-limiting findings often trigger protocol changes or cohort redesign. The decision underscores how mid-stage oncology programs can lose momentum quickly when toxicity profiles fail to match expected therapeutic windows. Investors will likely watch whether Amplia can recalibrate dosing, change schedule, or refine patient selection before resuming enrollment.